首页> 外文OA文献 >Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction
【2h】

Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction

机译:CRISPR / CAS9介导的基因校正拯救Cockayne综合征干细胞过早老化缺陷

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Cockayne syndrome (CS) is a rare autosomal recessive inherited disorder characterized by a variety of clinical features, including increased sensitivity to sunlight, progressive neurological abnormalities, and the appearance of premature aging. However, the pathogenesis of CS remains unclear due to the limitations of current disease models. Here, we generate integration-free induced pluripotent stem cells (iPSCs) from fibroblasts from a CS patient bearing mutations in CSB/ERCC6 gene and further derive isogenic gene-corrected CS-iPSCs (GC-iPSCs) using the CRISPR/Cas9 system. CS-associated phenotypic defects are recapitulated in CS-iPSC-derived mesenchymal stem cells (MSCs) and neural stem cells (NSCs), both of which display increased susceptibility to DNA damage stress. Premature aging defects in CS-MSCs are rescued by the targeted correction of mutant ERCC6. We next map the transcriptomic landscapes in CS-iPSCs and GC-iPSCs and their somatic stem cell derivatives (MSCs and NSCs) in the absence or presence of ultraviolet (UV) and replicative stresses, revealing that defects in DNA repair account for CS pathologies. Moreover, we generate autologous GC-MSCs free of pathogenic mutation under a cGMP (Current Good Manufacturing Practice)-compliant condition, which hold potential for use as improved biomaterials for future stem cell replacement therapy for CS. Collectively, our models demonstrate novel disease features and molecular mechanisms and lay a foundation for the development of novel therapeutic strategies to treat CS.
机译:抽象科凯恩综合征(CS)是一种罕见的常染色体隐性遗传性疾病,其特征在于多种临床特征,包括对阳光增加的灵敏度,进行性神经异常,和过早老化的外观。然而,CS的发病机理是由于当前疾病模型的局限性仍不清楚。在这里,我们生成从使用CRISPR / Cas9系统从CSB / ERCC6基因和进一步导出等基因基因校正的CS-的iPSC(GC-的iPSC)的CS患者轴承突变成纤维细胞游离整合诱导的多能干细胞(iPS细胞)。 CS-相关的表型缺陷在CS-源自iPSC的概括间充质干细胞(MSC)和神经干细胞(NSCs),两者都显示增加的易感性对DNA损伤的应力。在CS-MSC的早衰缺陷是由突变体ERCC6的目标校正救出。我们接下来在不存在或紫外(UV)和复制应力的存在下,在CS-的iPSC和GC-的iPSC和它们的成体干细胞衍生物(MSC和神经干细胞)的转录组的风景图,揭示了在DNA修复帐户CS病理缺陷。此外,我们生成自体GC-MSC的一个cGMP(现行良好生产规范)标准的情况下,持有用作未来的干细胞替代治疗CS改善潜力的生物材料在自由的致病突变。总的来说,我们的模型表明新的疾病特点和分子机制,并为新的治疗策略来对待CS的发展奠定了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号